Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Marchetti

Showing results (191-200 of 450) with videos related to

Pageof 45
Sort By:
Medicine|July 26, 2018
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case reportAntonio Stigliano, Pina Lardo, Lidia Cerquetti, et al.
BMC Cancer|October 21, 2010
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II studyGemma Bruera, Alessandra Santomaggio, Katia Cannita, et al.
Breast (Edinburgh, Scotland)|November 28, 2008
Adjuvant endocrine therapy for perimenopausal women with early breast cancerOlaf Ortmann, Tanja Cufer, J Michael Dixon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 6, 2016
A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approachPaolo Marchetti, Barbara Pavan, Daniele Simoni, et al.
ACS Omega|February 9, 2026
Synthesis of a Cannabidiol Precursor: Experimental Challenges and DFT Insights into β‑Elimination BarriersMichael Bergami, Claudio Trapella, Greta Compagnin, et al.
Therapeutic Drug Monitoring|July 3, 2009
A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cellsAlfonso M Lostia, Luana Lionetto, Cristiano Ialongo, et al.
Analytical Cellular Pathology (Amsterdam)|April 24, 2018
Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical PracticeAnnalisa Milano, Francesca Mazzetta, Sabatino Valente, et al.
Oncotarget|January 27, 2018
Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenibSimona Caporali, Ester Alvino, Pedro Miguel Lacal, et al.
United European Gastroenterology Journal|September 20, 2018
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatmentGiulio Antonelli, Elia Gigante, Massimo Iavarone, et al.
Clinical Endocrinology|December 3, 2019
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?Emilia Sbardella, Marta Tenuta, Grazia Sirgiovanni, et al.
Pageof 45

Showing results (191-200 of 450) with videos related to

Sort By:
Pageof 45
Medicine|July 26, 2018
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case reportAntonio Stigliano, Pina Lardo, Lidia Cerquetti, et al.
BMC Cancer|October 21, 2010
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II studyGemma Bruera, Alessandra Santomaggio, Katia Cannita, et al.
Breast (Edinburgh, Scotland)|November 28, 2008
Adjuvant endocrine therapy for perimenopausal women with early breast cancerOlaf Ortmann, Tanja Cufer, J Michael Dixon, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|June 6, 2016
A novel hybrid drug between two potent anti-tubulin agents as a potential prolonged anticancer approachPaolo Marchetti, Barbara Pavan, Daniele Simoni, et al.
ACS Omega|February 9, 2026
Synthesis of a Cannabidiol Precursor: Experimental Challenges and DFT Insights into β‑Elimination BarriersMichael Bergami, Claudio Trapella, Greta Compagnin, et al.
Therapeutic Drug Monitoring|July 3, 2009
A liquid chromatography-tandem mass spectrometry method for the determination of 5-Fluorouracil degradation rate by intact peripheral blood mononuclear cellsAlfonso M Lostia, Luana Lionetto, Cristiano Ialongo, et al.
Analytical Cellular Pathology (Amsterdam)|April 24, 2018
Molecular Detection of EMT Markers in Circulating Tumor Cells from Metastatic Non-Small Cell Lung Cancer Patients: Potential Role in Clinical PracticeAnnalisa Milano, Francesca Mazzetta, Sabatino Valente, et al.
Oncotarget|January 27, 2018
Targeting the <i>PTTG1</i> oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenibSimona Caporali, Ester Alvino, Pedro Miguel Lacal, et al.
United European Gastroenterology Journal|September 20, 2018
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatmentGiulio Antonelli, Elia Gigante, Massimo Iavarone, et al.
Clinical Endocrinology|December 3, 2019
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?Emilia Sbardella, Marta Tenuta, Grazia Sirgiovanni, et al.
Pageof 45